Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia

References

• Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005; 5: 18
   PubMed Web of Science ®Google Scholar
• Richardson P G, Sonneveld P, Schuster M W, Irwin D, Stadtmauer E A, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498
   PubMed Web of Science ®Google Scholar
• San Miguel J F, Schlag R, Khuageva N K, Dimopoulos M A, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906–917
   PubMed Web of Science ®Google Scholar
• Kastritis E, Migkou M, Gavriatopoulou M, Zirogiannis P, Hadjikonstantinou V, Dimopoulos M A. Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica 2009; 94: 300–302
   PubMed Web of Science ®Google Scholar
• Hess G, Wagner V, Kreft A, Heussel C P, Huber C. Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease. Br J Haematol 2006; 134: 544–545
   PubMed Web of Science ®Google Scholar
• Wechalekar A D, Lachmann H J, Offer M, Hawkins P N, Gillmore J D. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008; 93: 295–298
   PubMed Web of Science ®Google Scholar
• Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007; 92: 1351–1358
   PubMed Web of Science ®Google Scholar
• Dimopoulos M A, Anagnostopoulos A, Kyrtsonis M C, Castritis E, Bitsaktsis A, Pangalis G A. Treatment of relapsed or refractory Waldenströms Macroglobulinemia with bortezomib. Haematologica 2005; 90: 1655–1658
   PubMed Web of Science ®Google Scholar
• Chen C I, Kouroukis C T, White D, Voralia M, Stadtmauer E, Stewart A K, et al. Bortezomib is active in patients with untreated or relapsed Waldenströms Macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1570–1575
   PubMed Web of Science ®Google Scholar
• Treon S P, Hunter Z R, Matous J, Joyce R M, Mannion B, Advani R, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenströms Macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007; 13: 3320–3325
   PubMed Web of Science ®Google Scholar
• Richardson P G, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110: 3557–3560
   PubMed Web of Science ®Google Scholar
• Kropff M H, Bisping G, Wenning D, Volpert S, Tchinda J, Berdel W E, et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 2005; 29: 587–590
   PubMed Web of Science ®Google Scholar
• Richardson P G, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005; 106: 2977–2981
   PubMed Web of Science ®Google Scholar
• Chang H, Trieu Y, Qi X, Xu W, Stewart K A, Reece D. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res 2007; 31: 779–782
   PubMed Web of Science ®Google Scholar
• Jagannath S, Richardson P G, Sonneveld P, Schuster M W, Irwin D, Stadtmauer E A, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007; 21: 151–157
   PubMed Web of Science ®Google Scholar
• Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng W J, Roels S, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007; 109: 3177–3188
   PubMed Web of Science ®Google Scholar
• Oerlemans R, Franke N E, Assaraf Y G, Cloos J, van Zantwijk I, Berkers C R, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008; 112: 2489–2499
   PubMed Web of Science ®Google Scholar
• Wang L, Kumar S, Fridley B L, Kalari K R, Moon I, Pelleymounter L L, et al. Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics. Clin Cancer Res 2008; 14: 3503–3513
   PubMed Web of Science ®Google Scholar
• Politou M, Karadimitris A, Terpos E, Kotsianidis I, Apperley J F, Rahemtulla A. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. Leuk Res 2006; 30: 240–241
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades C S, Richardson P G, Poulaki V, Tai Y T, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377–2380
   PubMed Web of Science ®Google Scholar
• Ma M H, Yang H H, Parker K, Manyak S, Friedman J M, Altamirano C, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136–1144
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades C S, Richardson P G, McMullan C, Poulaki V, Fanourakis G, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101: 4055–4062
   PubMed Web of Science ®Google Scholar
• Orlowski R Z, Voorhees P M, Garcia R A, Hall M D, Kudrik F J, Allred T, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058–3065
   PubMed Web of Science ®Google Scholar
• Orlowski R Z, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25: 3892–3901
   PubMed Web of Science ®Google Scholar
• Oakervee H E, Popat R, Curry N, Smith P, Morris C, Drake M, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 755–762
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades C S, Poulaki V, Chauhan D, Richardson P G, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525–4530
   PubMed Web of Science ®Google Scholar
• Richardson P G, Jagannath S, Avigan D E, Alsina M, Schlossman R, Mazumder A, et al. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase I trial. Abstract 108. American Society of Hematology, Annual Meeting. 2006
   Google Scholar
• Richardson P, Jagannath S, Raje N, Jakubowiak A, Lonial S, Ghobrial I, et al. Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): preliminary results of a phase II study. Abstract 2714. American Society of Hematology, Annual Meeting. 2007
   Google Scholar
• Richardson P, Jagannath S, Raje N, Jakubowiak A, Lonial S, Avigan D, et al. Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) as front-line therapy for patients with multiple myeloma (MM): preliminary results of a phase 1/2 study. Abstract 187. American Society of Hematology, Annual Meeting. 2007
   Google Scholar
• Richardson P G, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson P G, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165–172
   PubMed Web of Science ®Google Scholar
• Richardson P G, Briemberg H, Jagannath S, Wen P Y, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24: 3113–3120
   PubMed Web of Science ®Google Scholar
• Argyriou A A, Iconomou G, Kalofonos H P. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008; 112: 1593–1599
   PubMed Web of Science ®Google Scholar
• Windebank A J, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13: 27–46
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Nobile-Orazio E. Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologica 2007; 92: 1308–1310
   PubMed Web of Science ®Google Scholar
• Oken M M, Creech R H, Tormey D C, Horton J, Davis T E, McFadden E T, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655
   PubMed Web of Science ®Google Scholar
• Miller A B, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas A D, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176–181
   PubMed Web of Science ®Google Scholar
• Cella D. Manual of the functional assessment of chronic illness therapy (FACIT) measurement system. 4th ed. Evanston, IL 1997
   Google Scholar
• Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 2001; 17: 888–895
   PubMed Web of Science ®Google Scholar
• Amara S. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy. Ann Pharmacother 2008; 42: 1481–1485
   PubMed Web of Science ®Google Scholar
• Wang W S, Lin J K, Lin T C, Chen W S, Jiang J K, Wang H S, et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007; 12: 312–319
   PubMed Web of Science ®Google Scholar
• De Grandis D. Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review. CNS Drugs 2007; 21(Suppl 1)39–43, discussion 5–6
   PubMed Web of Science ®Google Scholar
• Ozyurek H, Turker H, Akbalik M, Bayrak A O, Ince H, Duru F. Pyridoxine and pyridostigmine treatment in vincristine-induced neuropathy. Pediatr Hematol Oncol 2007; 24: 447–452
   PubMed Web of Science ®Google Scholar
• Cleary J F. The pharmacologic management of cancer pain. J Palliat Med 2007; 10: 1369–1394
   PubMed Web of Science ®Google Scholar
• Lonial S, Waller E K, Richardson P G, Jagannath S, Orlowski R Z, Giver C R, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106: 3777–3784
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J L, Stoppa A M, Sotto J J, Fuzibet J G, Rossi J F, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Vesole D H, Naucke S, Cheson B, Mattox S, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789–793
   PubMed Web of Science ®Google Scholar
• Blade J, Rosinol L, Sureda A, Ribera J M, Diaz-Mediavilla J, Garcia-Larana J, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755–3759
   PubMed Web of Science ®Google Scholar
• Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037–1043
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J L, Facon T, Guilhot F, Doyen C, Fuzibet J G, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502
   PubMed Web of Science ®Google Scholar
• Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25: 2434–2441
   PubMed Web of Science ®Google Scholar
• Harousseau J L, Palumbo A, Richardson P, Schlag R, Dimopoulos M, Shpilberg O, et al. Superior outcomes associated with complete response: analysis of the phase III Vista study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Abstract 2778. American Society of Hematology, Annual Meeting. 2008
   Google Scholar
• Koreth J, Cutler C S, Djulbegovic B, Behl R, Schlossman R L, Munshi N C, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007; 13: 183–196
   PubMed Web of Science ®Google Scholar
• Harousseau J L, Mathiot C, Attal M, Marit G, Caillot D, Mohty M, et al. Velcade/dexamethasone (Vel/D) versus VAD as induction treartment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial. Abstract 450. American Society of Hematology Annual Meeting. 2007
   Google Scholar
• Sunwoo J B, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7: 1419–1428
   PubMed Web of Science ®Google Scholar
• Cavo M, Tacchetti P, Patriarca F, Petrucci M T, Pantani L, Ceccolini M, et al. Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma. Abstract 1662. American Society of Hematology, Annual Meeting. 2008
   Google Scholar
• Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138: 176–185
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J L, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289–3294
   PubMed Web of Science ®Google Scholar
• Abdelkefi A, Ladeb S, Torjman L, Othman T B, Lakhal A, Romdhane N B, et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 2008; 111: 1805–1810
   PubMed Web of Science ®Google Scholar
• Sonneveld P, van der Holt B, Schmidt-Wolf I GH, Bertsch U, el Jarari L, Salwender H J, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM). Abstract 653. American Society of Hematology, Annual Meeting. 2008
   Google Scholar
• Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005; 8: 407–419
   PubMed Web of Science ®Google Scholar
• Richardson P, Hofmeister C C, Zimmerman T M, Chanan-Khan A A, Spear M, Palladino M AA, et al. Phase 1 clinical trial of NPI-0052, a novel proteasome inhibitor in patients with multiple myeloma. Abstract 2770. American Society of Hematology, Annual Meeting. 2008
   Google Scholar
• Demo S D, Kirk C J, Aujay M A, Buchholz T J, Dajee M, Ho M N, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67: 6383–6391
   PubMed Web of Science ®Google Scholar
• Vij R, Wang M, Orlowski R, Stewart A K, Jagannath S, Kukreti W, et al. Initial results of PX-171-004, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed Myeloma (MM). Abstract 865). American Society of Hematology, Annual Meeting. 2008
   Google Scholar
• Jagannath S, Vij R, Stewart A K, Somlo G, Jakubowiak A, Reiman T, et al. Initial results of PX-171-003, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma (MM). Abstract 864. American Society of Hematology, Annual Meeting. 2008
   Google Scholar
• Roccaro A M, Leleu X, Sacco A, Jia X, Melhem M, Moreau A S, et al. Dual targeting of the proteasome regulates survival and homing in Waldenström Macroglobulinemia. Blood 2008; 111: 4752–4763
   PubMed Web of Science ®Google Scholar